Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Positive IIb Results for Sarepta | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Positive IIb Results for Sarepta

96-week results are good for eteplirsen in patients with DMD

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Sarepta Therapeutics has posted data through Week 96 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). Results through nearly two years showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the six-minute walk test (6MWT). Study 202 earlier met its primary endpoint of increased novel dystrophin, as assessed by muscle biopsy at Week 48, and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes.

Through 96 weeks, eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events, no treatment-related serious adverse events, hospitalizations or discontinuations. Sarepta plans to file an NDA for eteplirsen in 1H14.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics